ADC Therapeutics SA (ADCT) vs PepGen (PEPG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
PepGen (PEPG) has outperformed ADC Therapeutics SA (ADCT) over the past year, losing 46.8% versus a loss of 65.7%. PepGen is the larger company by market cap ($179.8 million vs $178.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADCT | PEPG |
|---|---|---|
| Share price | $1.40 | $2.60 |
| Market cap | $178.73M | $179.84M |
| 1-day change | -6.04% | +2.77% |
| YTD return | -60.34% | -60.06% |
| 1-year return | -65.69% | -46.83% |
| 5-year return | -94.64% | — |
| EPS (TTM) | $-0.60 | $-1.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $81.36M | — |
| Revenue growth (YoY) | +14.85% | — |
| Net income (latest FY) | $-142.62M | $-89.66M |
| Gross margin | 92.87% | — |
| Operating margin | -149.34% | — |
| Net margin | -175.31% | — |
| 52-week high | $4.98 | $7.80 |
| 52-week low | $0.78 | $1.31 |
| Distance from 52-week high | -71.89% | -66.67% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +137.86% | +291.92% |
| Average volume | 1.53M | 864.38K |
| Shares outstanding | 127.67M | 69.17M |
| Employees | 188 | 57 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PEPG has outperformed ADCT by 18.9 percentage points over the past year.
About ADC Therapeutics SA
ADCT stock →ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.
Health Care · Biotechnology: Pharmaceutical Preparations · 188 employees
About PepGen
PEPG stock →PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1.
Health Care · Biotechnology: Pharmaceutical Preparations · 57 employees
ADCT vs PEPG FAQ
Which is bigger, ADC Therapeutics SA or PepGen?
PepGen (PEPG) is larger, with a market capitalization of $179.84M compared with $178.73M for ADC Therapeutics SA (ADCT).
Which stock has performed better over the past year, ADCT or PEPG?
PEPG returned -46.83% over the past 12 months, compared with -65.69% for ADCT (price return, excluding dividends). Past performance does not predict future results.
Are ADC Therapeutics SA and PepGen in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.